7/103 sources · 3 publishersUpdated Oct 9, 00:40 UTC
JPMorgan initiates Overweight coverage on Neurogene with $60 price target
JPMorgan began coverage of Neurogene Inc., assigning an Overweight rating and a $60.00 price target. The firm highlighted the company's NGN‑401 gene therapy for Rett syndrome as the catalyst. Neurogene’s shares were trading at $25.87, down 32% over the prior three months, and the bank expects new trial data in 2027 to drive further upside.
Why it matters
JPMorgan’s target implies a 132% upside from the current price, which could attract investors seeking biotech exposure. The rating and target may increase trading volume and influence analyst consensus on the stock.
Key facts
- 1JPMorgan set a price target of $60.00 for Neurogene. investing.com
- 2Neurogene’s stock was trading at $25.87. investing.com
- 3The company’s market cap is $518 million. investing.com
- 4Neurogene has a beta of 2.09. investing.com
- 5Neurogene’s current ratio is 10.64. investing.com
- 6JPMorgan’s target implies a 132% upside. cnbc.com
Summary written by AlphAI from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.